How should tigecycline be administered intravenously, including dosing, infusion duration, and adjustments for hepatic impairment and pediatric patients?

How to Administer Tigecycline

Administer tigecycline as a 100 mg IV loading dose followed by 50 mg IV every 12 hours, infused over 30-60 minutes, with dose reduction to 25 mg every 12 hours only in patients with severe hepatic impairment (Child-Pugh C). 1

Standard Adult Dosing

• Loading dose: 100 mg IV
• Maintenance dose: 50 mg IV every 12 hours
• Infusion duration: 30-60 minutes per dose 1
• Treatment duration:
  • 5-14 days for complicated skin/skin structure infections and complicated intra-abdominal infections
  • 7-14 days for community-acquired bacterial pneumonia 1

Hepatic Impairment Adjustments

No dose adjustment is needed for mild to moderate hepatic impairment (Child-Pugh A and B). 1 However, patients with severe hepatic impairment require specific modifications:

• Child-Pugh C (severe): 100 mg loading dose, then 25 mg every 12 hours (50% reduction in maintenance dose) 1
• Monitor these patients closely for treatment response and adverse effects 1

Important caveat: Recent pharmacokinetic data shows that patients with severe hepatic impairment achieve significantly higher drug exposures and face increased risk of hypofibrinogenemia—all 6 patients with Child-Pugh C in one study developed this complication 2. The guideline recommendation to use tigecycline cautiously in patients with liver insufficiency is well-founded 3.

Pediatric Dosing

Avoid tigecycline in pediatric patients unless no alternative antibacterial drugs are available due to observed increased mortality in adults and lack of safety/efficacy data in children. 1

When absolutely necessary:

• Ages 8-11 years: 1.2 mg/kg IV every 12 hours (maximum 50 mg per dose) 4, 1
• Ages 12-17 years: 50 mg IV every 12 hours 4, 1
• No data available for dosing in pediatric patients with hepatic impairment 1

Recent pediatric studies suggest these doses may be insufficient for less susceptible pathogens, particularly for complicated intra-abdominal infections requiring up to twice the standard dose 5. However, given the mortality concerns and limited safety data, consultation with pediatric infectious disease specialists is strongly advised before use 4.

Preparation and Administration

Reconstitution:

1. Add 5.3 mL of 0.9% Sodium Chloride, 5% Dextrose, or Lactated Ringer's to each vial
2. Gently swirl until dissolved (achieves 10 mg/mL concentration)
3. Withdraw 5 mL of reconstituted solution
4. Add to 100 mL IV bag for infusion (maximum concentration 1 mg/mL)
5. Solution should be yellow to orange; discard if green or black 1

Storage after reconstitution:

• Room temperature (≤25°C): up to 24 hours total (6 hours in vial + remaining time in IV bag)
• Refrigerated (2-8°C): up to 48 hours (only with 0.9% Sodium Chloride or 5% Dextrose) 1

Administration route:

• Dedicated IV line OR Y-site compatible with multiple agents (amikacin, dopamine, gentamicin, morphine, norepinephrine, propofol, etc.) 1
• Flush line before and after with compatible solution if using sequential infusions 1

Critical Clinical Considerations

Do NOT use tigecycline for:

• Hospital-acquired or ventilator-associated pneumonia (associated with greater mortality and decreased efficacy) 1
• Diabetic foot infections (failed to demonstrate non-inferiority) 1

Combination therapy is standard practice: In real-world use, tigecycline is typically combined with other antimicrobials (colistin, aminoglycosides, carbapenems) for multidrug-resistant infections 3, 4. For carbapenem-resistant Enterobacterales intra-abdominal infections, the guideline specifically recommends tigecycline 100 mg loading dose then 50 mg every 12 hours 4.

MIC considerations: Tigecycline efficacy is MIC-dependent. For CRAB infections, success rates are higher when MIC ≤2 mg/L; efficacy becomes inferior to polymyxin when MIC >2 mg/L 3. Determine MIC before treatment initiation when possible 3.

Mortality data: Analysis of pediatric cases shows mortality in bloodstream infections was 86% versus 24% in non-bacteremic cases (P=0.009) 6. This underscores the importance of reserving tigecycline for situations with no alternatives and avoiding it as monotherapy for bacteremia.